Study ID

49653/452

Clinical Study ID

49653/452

Study Title A randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability and efficacy of six months' administration of AVANDIA (rosiglitazone maleate) in subjects with Relapsing-Remitting Multiple Sclerosis (MS)
Patient Level Data Study Listed on ClinicalStudyDataRequest.com
Clinicaltrials.gov Identifier
Sponsor GlaxoSmithKline
Collaborators N/A
Phase phase 2
Study Recruitment Status Completed
Generic Name rosiglitazone
Trade Name Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia
Study Indication Multiple Sclerosis, Relapsing-Remitting

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.